Healthcare

LTR Pharma Limited (ASX: LTP) has completed an important step in its United States commercialisation strategy by securing definitive agreements covering both the manufacturing and distribution of its intranasal erectile dysfunction therapy, ROXUS. While these agreements establish the commercial framework for launch, they should …

SomnoMed reported record half-year revenue of AUD 60.7 million and EBITDA of AUD 7.8 million, up 35%, on 27 February 2026; no FY26 full-year result had been lodged by 27 July 2026.

Aroa Biosurgery Limited (ASX:ARX) reported FY26 revenue of NZD 103.9 million, up 23% and above its own NZD 92-100 million guidance range.

Paradigm Biopharmaceuticals Limited (ASX:PAR) lodged an announcement titled "PAR Completes Enrolment in Pivotal Phase 3" on 15 June 2026, closing recruitment into study PARA_OA_012.

Proteomics International Laboratories Limited (ASX:PIQ) drew market attention after appointing Healius Limited (ASX:HLS) as exclusive Australian distributor for its Promarker blood tests. The three-year agreement, announced on 22 July 2026, provides access to a national pathology network and includes an option for a further …

Optiscan Imaging (ASX:OIL) is pushing two of its most closely watched cancer studies forward at once, and the market is paying attention. The Melbourne-based medical technology company has advanced its head and neck cancer trial into a live surgical imaging phase ahead of schedule, …

LTR Pharma (ASX:LTP) has spent the past two years building an unusual proposition on the ASX small-cap boards: a fast-acting nasal spray for erectile dysfunction that aims to work in minutes rather than the half-hour or more that familiar oral tablets typically demand. Through …